🧫
cGAMP biomarker analysis in ALS patient spinal cord samples
active
experiment
Created: 2026-04-06T12:28:36
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-171a9eac-18ec-44fd-a73e-d3e1d331a5fa
🧫 Experiment Protocol
Clinicalamyotrophic lateral sclerosishuman patientsproposed
Analysis of spinal cord tissue samples from ALS patients to measure levels of cyclic GMP-AMP (cGAMP), the specific metabolite produced by cGAS activation. This study aimed to validate the clinical relevance of cGAS/STING pathway activation in human ALS and establish cGAMP as a potential biomarker for mitochondrial DNA release and innate immune activation in ALS patients.
PRIMARY OUTCOME
cGAMP levels in spinal cord tissue
EXPECTED OUTCOMES
Elevated cGAMP levels in ALS patient spinal cord samples
SUCCESS CRITERIA
Significantly higher cGAMP levels in ALS patients versus controls
PROTOCOL
Measurement of cGAMP metabolite levels in post-mortem spinal cord samples from ALS patients compared to controls
Source: PMID 33031745 ↗
🧫 Experiment Extras
PATHWAY
cGAS/STING innate immune signaling
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.